Pirtobrutinib Application Scope

Mantle Cell Lymphoma (MCL): Pirtobrutinib is indicated for the treatment of adult patients with relapsed or refractory MCL who have received at least two prior lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.

Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL): Pirtobrutinib is indicated for the treatment of adult patients with CLL or SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

Pirtobrutinib Characteristics

Ingredients: Each tablet contains pirtobrutinib as the active ingredient.
Properties: It is a non-covalent (reversible) BTK inhibitor that binds to and inhibits both wild-type and mutant BTK-mediated signaling, thereby inhibiting B-cell proliferation and survival.
Specification: It is available in tablet form for oral administration in strengths of 50 mg and 100 mg.
Packaging Specification: Specific packaging specifications are not detailed in the provided sources.
Storage: Store at room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F).
Expiry Date: Information regarding the shelf life or expiry date is not available in the provided sources.
Executive Standard: Pirtobrutinib has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Approval Number: Specific approval numbers are not mentioned in the provided sources.
Date of Revision: The prescribing information was last updated in January 2024.
Manufacturer: Eli Lilly and Company.

Guidelines for the Use of Pirtobrutinib

Dosage and Administration:
- The recommended dosage is 200 mg orally once daily, continued until disease progression or unacceptable toxicity.
Adverse Reactions:
- Common adverse reactions (≥20%) include fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising.
Contraindications:
- There are no contraindications listed in the prescribing information.
Precautions:
- Monitor for infections, hemorrhage, cytopenias, cardiac arrhythmias, and secondary primary malignancies.

Pirtobrutinib Interactions

Drug Interactions:
- Avoid coadministration with strong CYP3A inhibitors; if unavoidable, reduce its dose to 50 mg.
- Avoid coadministration with strong or moderate CYP3A inducers; if unavoidable, adjust its dosage accordingly.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.